Sanofi Cuts 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases
Sanofi reportedly ended 38 R&D programs and is prioritizing oncology, immunology, rare disease and rare blood disorders.
Exclusive: Teva’s generic EpiPen launch stalls months after approval
Many of the largest U.S. pharmacies and drug distributors do not have Teva Pharmaceutical Industries Ltd.’s generic version of EpiPen five months after the life-saving allergy treatment was approved for sale in the United States, pharmacy chains and a group that tracks drug shortages told Reuters.
FDA Approves Imbruvica for 10th Time
FDA approved Imbruvica combined with Gazyva for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Lilly’s cancer therapy Lartruvo fails study, shares drop
Eli Lilly’s shares fell after the cancer treatment Lartruvo – approved on an accelerated basis in 2016 – failed to improve patient survival in a long-term study and will no longer be prescribed.
Ionis and Roche agree on dry AMD treatment deal
Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.
HIV Treatments That Could Make Redfield’s Prediction a Reality to Defeat AIDS Epidemic
Dr. Robert Redfield, the new head of the U.S. Centers for Disease Control and Prevention, boldly predicted in April 2018 that the AIDS epidemic can be defeated by 2025. Merck, Janssen and Gilead Sciences all released clinical data for HIV treatments that could make Redfield’s prediction a reality.
J&J, Arrowhead reach gene-silencing drug deal
J&J agreed to develop and market Arrowhead Pharmaceuticals Inc.’s gene-silencing hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion.
One Drop’s Apple Watch App Points to Trend in Wearable Health Devices
Personalized medicine continues to grow in importance, and having the ability to monitor health data has proven to be a significant desire for people as the number of wearable devices continues to grow.
Supernus Pharma to Buy Biscayne Neurotherapeutics in Potential $183 Million Deal
Rockville, Maryland-based Supernus Pharmaceuticals is acquiring Biscayne Neurotherapeutics, which is located in Miami.
Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck KGaA, Pfizer
Checkmate Pharmaceuticals announced a clinical trial collaboration and supply agreement with the alliance between Merck KGaA and Pfizer Inc. to evaluate the TLR9 agonist CMP-001 in combination with the human anti-PD-L1 antibodyavelumab.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!